To investigate whether CXCL12 upregulates FOLR1 to induce sorafenib resistance in HCC cells through CXCR4, we inhibited CXCR4 in HCC cells and subsequently treated them with CXCL12 protein or CAF supernatant. This evidence concerns the gene CXCR4 and hepatocellular carcinoma.